Dopaminergic mechanism of reward-related incentive learning: focus on the dopamine D(3) receptor.
Dopamine D(3) receptors (Drd3) have been implicated in the control of responding by drug-related conditioned incentive stimuli. We review recent studies of the effects of Drd3 antagonists or partial agonists on the control of self-administration of intravenous (IV) cocaine, IV morphine and oral ethanol on reward-rich and lean schedules, in reinstatement tests, on second-order schedules and on the acquisition and expression of conditioned place preference (CPP) and conditioned motor activity. For comparison, related studies where conditioned stimuli are based on nutritional reward also are considered. When self-administration depends more heavily on conditioned cues for its maintenance, for example on second-order schedules or lean ratio schedules, Drd3 antagonists or partial agonists reduce responding. Although data are limited, similar effects may be seen for responding for cues based on drugs or nutritional rewards. Drd3 agents also block the ability of conditioned cues to reinstate responding for cocaine or food. Published results suggest that Drd3 plays a more important role in the expression than in the acquisition of a CPP or conditioned motor activity. The mechanism mediating the role of Drd3 in the control of responding by conditioned incentive stimuli remains unknown but it has been found that Drd3 receptors increase in number in the nucleus accumbens during conditioning. Perhaps Drd3 participates in the molecular mechanisms underlying the role of dopamine and of dopamine receptor subtypes in reward-related incentive learning.
Beninger
R J
RJ
Department of Psychology, and Centre for Neuroscience Studies, Queen's University, Kingston ON, K7L 3N6 Canada. Beninger@queensu.ca
Banasikowski
T J
TJ
D000818:Animals; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D007858:Learning / Q000502:physiology*; D009042:Motivation; D050637:Receptors, Dopamine D3 / Q000502:physiology*; D012201:Reward
D050637:Receptors, Dopamine D3; D004298:Dopamine
Neuropsychopharmacology. 2003 Nov;28(11):1903-15
12915863
Psychopharmacologia. 1967;11(1):88-94
5596864
Psychopharmacology (Berl). 1998 Dec;140(3):331-44
9877013
Neuropsychopharmacology. 2005 Apr;30(4):720-30
15562293
Brain Res. 1993 Nov 26;629(1):31-9
8287278
Pharmacol Biochem Behav. 2005 Dec;82(4):727-34
16405981
Brain Res Brain Res Rev. 1998 Dec;28(3):309-69
9858756
J Pharmacol Exp Ther. 2007 May;321(2):573-82
17272677
CNS Drug Rev. 2007 Summer;13(2):240-59
17627675
Neurosci Biobehav Rev. 1989 Summer-Fall;13(2-3):113-22
2573022
Psychopharmacology (Berl). 1996 Oct;127(3):213-24
8912399
Nature. 1999 Jul 22;400(6742):371-5
10432116
Neurotox Res. 2004;6(1):91-104
15184110
Science. 1997 Mar 14;275(5306):1593-9
9054347
J Pharmacol Exp Ther. 2007 Mar;320(3):1268-78
17170312
Pavlov J Biol Sci. 1976 Oct-Dec;11(4):222-36
1033507
Synapse. 2003 Jun 1;48(3):154-6
12645041
Prog Neurobiol. 1998 Dec;56(6):613-72
9871940
Psychopharmacology (Berl). 1982;77(4):379-82
6813901
Neuroreport. 2003 Jan 20;14(1):93-8
12544838
Neuropsychopharmacology. 2003 Feb;28(2):329-38
12589386
Addict Biol. 2007 Mar;12(1):35-50
17407496
Prog Neurobiol. 1990;34(2):143-83
1969668
J Neurosci. 2002 Nov 1;22(21):9595-603
12417684
Brain Res. 1995 Mar 6;673(2):242-50
7606438
Eur J Neurosci. 2002 Jun;15(12):2016-26
12099907
Neuropsychopharmacology. 2003 Jun;28(6):1150-9
12700684
Neuropsychopharmacology. 2006 Jul;31(7):1393-405
16205781
Brain Res. 1986 Dec 3;399(1):33-41
3026573
Brain Res. 1983 Oct;287(2):173-96
6357357
Neuroreport. 2004 Oct 5;15(14):2245-9
15371743
Drug Alcohol Depend. 2006 Jan 4;81(1):63-70
16005579
Pharmacol Biochem Behav. 2006 Mar;83(3):456-64
16631246
Neurosci Lett. 1996 Jun 21;211(2):73-6
8830847
Neurosci Biobehav Rev. 2000 Jan;24(1):125-32
10654668
Brain Res Bull. 2003 Oct 15;61(6):595-601
14519456
Eur J Pharmacol. 1999 Jun 30;375(1-3):13-30
10443561
Neuroreport. 2002 Jan 21;13(1):173-6
11924883
Psychopharmacology (Berl). 1981;75(2):134-43
6798603
J Pharmacol Exp Ther. 2010 Nov;335(2):506-15
20724485
Science. 1978 Jul 21;201(4352):262-4
566469
Pharmacol Biochem Behav. 2008 Jun;89(4):499-507
18329700
FASEB J. 2006 Nov;20(13):2223-33
17077299
Behav Neurosci. 2008 Feb;122(1):129-39
18298256
Pharmacol Biochem Behav. 2005 May;81(1):190-7
15894078
Chembiochem. 2004 Apr 2;5(4):508-18
15185375
Neurosci Biobehav Rev. 1998 Mar;22(2):335-45
9579323
Neuropsychopharmacology. 2004 Aug;29(8):1479-87
15100700
Behav Neurosci. 2004 Dec;118(6):1324-30
15598141
J Pharmacol Exp Ther. 1973 Jul;186(1):18-30
4198773
Synapse. 2005 Jul;57(1):17-28
15858839
Nature. 1981 Nov 26;294(5839):366-8
6273735
Curr Opin Neurobiol. 1996 Apr;6(2):228-36
8725965
Behav Pharmacol. 2005 May;16(3):181-6
15864073
Eur J Neurosci. 2005 Jun;21(12):3427-38
16026480
J Neurosci. 2000 Oct 1;20(19):7489-95
11007908
Int J Neuropsychopharmacol. 2006 Oct;9(5):585-602
16942635
Psychopharmacology (Berl). 2007 Sep;193(4):475-86
17492273
Nat Med. 2003 Jun;9(6):762-7
12740572
Int J Neuropsychopharmacol. 2007 Apr;10(2):167-81
16426478
Brain Res Brain Res Rev. 2005 Jul;49(1):77-105
15960988
Eur J Pharmacol. 2007 Mar 22;559(2-3):173-9
17303116
Pharmacol Rev. 1997 Sep;49(3):231-52
9311022